American Healthcare REIT (AHR) director Jeffrey T. Hanson sold 20,010 shares for $994,104 at an average of $49.68 on November 10, 2025, ahead of its Q3 earnings report, with the stock near its 52-week high and deemed overvalued by InvestingPro. This transaction occurs as AHR recently reported a 22% year-over-year increase in Q3 2025 normalized FFO to $0.44 per share, exceeding analyst expectations, and raised its full-year guidance, prompting Citizens to increase its price target to $60 with a Market Outperform rating.
American Healthcare REIT (AHR) director Jeffrey T. Hanson sold 20,010 shares for $994,104 at an average price of $49.68 on November 10, 2025. This transaction occurred just two days prior to the company's Q3 earnings report, with AHR trading near its 52-week high of $50.51 and exhibiting 92% momentum over the past year. InvestingPro analysis suggests the stock is currently overvalued, trading above its fair value. Despite the insider sale, AHR reported robust Q3 2025 normalized Funds From Operations (FFO) of $0.44 per share, marking a significant 22% year-over-year increase and surpassing analyst expectations of $0.42. The company further demonstrated confidence by raising its full-year 2025 normalized FFO guidance to a range of $1.69 to $1.72 per share. This marks the third consecutive quarter that AHR has exceeded earnings forecasts. Following these strong results, Citizens upgraded its price target for AHR from $50 to $60, while maintaining a "Market Outperform" rating. The consistent outperformance is primarily attributed to higher net operating income generated from its RIDEA assets. These developments underscore a period of strong operational and financial execution for American Healthcare REIT.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
